Amylon is a CNS company that uses an ultra-genetics approach to confront global disease. This means that we focus on rare genetic disorders that have the potential to unlock therapies for patients worldwide. This opportunity allows us to focus on orphan disorders as a gateway to global disease, targeting the genetic and the sporadic patient populations.
Amylon uses the next generation of RNA Therapeutics to target genetic disorders at the RNA level. By manipulating the RNA we are able to target toxic protein formation at the source and impact disease at the earliest stage.
Amylon Therapeutics and Alcyone Lifesciences have partnered to combine Amylon’s next generation of Antisense Oligonucleotides with Alcyone’s revolutionary delivery technology.